Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 91, Issue 1, Pages 101-108
Publisher
Springer Nature
Online
2011-12-01
DOI
10.1038/clpt.2011.275
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Circulating Tumor Cells as Biomarkers in Prostate Cancer
- (2011) D. C. Danila et al. CLINICAL CANCER RESEARCH
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
- (2011) Elahe A. Mostaghel et al. CLINICAL CANCER RESEARCH
- Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response
- (2011) C. J. Ryan et al. CLINICAL CANCER RESEARCH
- The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature
- (2011) Guru Sonpavde et al. EUROPEAN UROLOGY
- Flushing Oral Oncology Drugs Down the Toilet
- (2011) Mark J. Ratain JOURNAL OF CLINICAL ONCOLOGY
- Expanding Treatment Options for Metastatic Prostate Cancer
- (2011) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
- (2011) Emma Hörnberg et al. PLoS One
- PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer
- (2010) Tarek A. Bismar et al. BJU INTERNATIONAL
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids
- (2010) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Reply to G. Attard et al
- (2010) Charles J. Ryan JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
- (2010) Alison H.M. Reid et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
- (2010) Howard I Scher et al. LANCET
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy
- (2009) Juan Morote et al. BJU INTERNATIONAL
- Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy
- (2009) Peyman Hadji CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer
- (2009) Prateek Mendiratta et al. JOURNAL OF CLINICAL ONCOLOGY
- New Developments in the Medical Management of Prostate Cancer
- (2009) Manish Kohli et al. MAYO CLINIC PROCEEDINGS
- Is PTEN loss associated with clinical outcome measures in human prostate cancer?
- (2008) P McCall et al. BRITISH JOURNAL OF CANCER
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor inactivation contributes to antitumor efficacy of 17 -hydroxylase/17,20-lyase inhibitor 3 -hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
- (2008) T. Vasaitis et al. MOLECULAR CANCER THERAPEUTICS
- Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure
- (2007) Carsten Jagusch et al. BIOORGANIC & MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now